ATE383867T1
(de)
†
|
1997-11-14 |
2008-02-15 |
Amylin Pharmaceuticals Inc |
Neuartige exendin agonisten
|
AU770712B2
(en)
|
1999-01-14 |
2004-02-26 |
Amylin Pharmaceuticals, Inc. |
Methods for glucagon suppression
|
KR100675711B1
(ko)
|
1999-01-14 |
2007-02-01 |
아밀린 파마슈티칼스, 인크. |
신규 엑센딘 아고니스트 제제 및 이의 투여 방법
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
US6444788B1
(en)
|
1999-03-15 |
2002-09-03 |
Novo Nordisk A/S |
Ion exchange chromatography of GLP-1, analogs and derivatives thereof
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
AU754770B2
(en)
|
1999-05-17 |
2002-11-21 |
Conjuchem Biotechnologies Inc. |
Long lasting insulinotropic peptides
|
US6506724B1
(en)
*
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
EP1076066A1
(en)
*
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
ATE346093T1
(de)
|
2000-06-16 |
2006-12-15 |
Lilly Co Eli |
Analoge des glucagon ähnlichen peptid-1
|
EA005584B1
(ru)
|
2000-12-07 |
2005-04-28 |
Эли Лилли Энд Компани |
Слитые белки glp-1
|
ATE450269T1
(de)
|
2000-12-14 |
2009-12-15 |
Amylin Pharmaceuticals Inc |
Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
|
WO2002066511A2
(en)
|
2001-02-16 |
2002-08-29 |
Conjuchem Inc. |
Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
|
CN1162446C
(zh)
*
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
MXPA04001560A
(es)
|
2001-08-28 |
2004-05-17 |
Lilly Co Eli |
Premezclas de glp-1 e insulina basal.
|
WO2003035099A1
(en)
|
2001-10-19 |
2003-05-01 |
Eli Lilly And Company |
Biphasic mixtures of glp-1 and insulin
|
US20050148497A1
(en)
|
2002-02-20 |
2005-07-07 |
Khan Mohammed A. |
Method for administering glp-1 molecules
|
EP1525219B1
(en)
|
2002-07-04 |
2009-05-27 |
Zealand Pharma A/S |
Glp-1 and methods for treating diabetes
|
RU2376314C2
(ru)
|
2002-10-02 |
2009-12-20 |
Зилэнд Фарма А/С |
Стабилизированные соединения эксендина-4
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
EP1631308B1
(en)
|
2003-05-30 |
2013-07-31 |
Amylin Pharmaceuticals, LLC |
Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
CN1961000B
(zh)
|
2004-02-11 |
2011-05-04 |
安米林药品公司 |
具有可选择特性的杂合多肽
|
JP5638177B2
(ja)
|
2004-02-11 |
2014-12-10 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
|
US8114958B2
(en)
|
2004-02-11 |
2012-02-14 |
Amylin Pharmaceuticals, Inc. |
Amylin family peptides
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
CN101035806A
(zh)
|
2004-10-08 |
2007-09-12 |
安米林药品公司 |
新的糊精家族多肽-6(afp-6)类似物和制备和使用它们的方法
|
CN101094689B
(zh)
|
2004-11-01 |
2013-06-12 |
安米林药品有限责任公司 |
治疗肥胖以及肥胖相关疾病和病症的方法
|
EP1841796A2
(en)
|
2004-12-02 |
2007-10-10 |
Domantis Limited |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
SG158141A1
(en)
|
2004-12-13 |
2010-01-29 |
Amylin Pharmaceuticals Inc |
Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
|
US8404637B2
(en)
|
2005-02-11 |
2013-03-26 |
Amylin Pharmaceuticals, Llc |
GIP analog and hybrid polypeptides with selectable properties
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
WO2006110887A2
(en)
|
2005-04-11 |
2006-10-19 |
Amylin Pharmaceuticals, Inc |
Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
|
CN100429227C
(zh)
*
|
2005-06-29 |
2008-10-29 |
常州制药厂有限公司 |
Exendin4多肽片段
|
EP1922336B1
(en)
|
2005-08-11 |
2012-11-21 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
WO2008047241A2
(en)
|
2006-10-16 |
2008-04-24 |
Conjuchem Biotechnologies Inc. |
Modified corticotropin releasing factor peptides and uses thereof
|
RU2413528C2
(ru)
|
2007-01-18 |
2011-03-10 |
Открытое Акционерное Общество "Валента Фармацевтика" |
Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
|
WO2008148839A2
(en)
|
2007-06-08 |
2008-12-11 |
Ascendis Pharma As |
Long-acting polymeric prodrugs of exendin
|
ATE520714T1
(de)
|
2007-06-15 |
2011-09-15 |
Zealand Pharma As |
Glucagonanaloga
|
CA2718480A1
(en)
|
2008-03-31 |
2009-10-08 |
Glaxo Group Limited |
Drug fusions and conjugates
|
ES2552646T3
(es)
|
2008-05-21 |
2015-12-01 |
Amylin Pharmaceuticals, Inc. |
Exendinas para disminuir el colesterol y los triglicéridos
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102008051834A1
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102009038210A1
(de)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
PT3228320T
(pt)
|
2008-10-17 |
2020-03-26 |
Sanofi Aventis Deutschland |
Combinação de uma insulina e de um agonista do glp-1
|
CA2747109A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
JP5635530B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
BRPI0823377A2
(pt)
|
2008-12-15 |
2016-09-27 |
Zealand Pharma As |
análogos de glucagon
|
KR20110126591A
(ko)
|
2008-12-15 |
2011-11-23 |
질랜드 파마 에이/에스 |
글루카곤 유사체
|
JP2012521971A
(ja)
|
2009-03-27 |
2012-09-20 |
グラクソ グループ リミテッド |
薬物融合体および複合体
|
WO2010138671A1
(en)
|
2009-05-28 |
2010-12-02 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds for sleep enhancement
|
PE20121130A1
(es)
|
2009-07-13 |
2012-08-30 |
Zealand Pharma As |
Analogos de glucagon acilados
|
JP5732053B2
(ja)
|
2009-07-31 |
2015-06-10 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
持続型インスリン組成物
|
JP5738291B2
(ja)
|
2009-07-31 |
2015-06-24 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
インスリンリンカー複合体を含むプロドラッグ
|
SG10201406063XA
(en)
|
2009-09-30 |
2014-11-27 |
Glaxo Group Ltd |
Drug fusions and conjugates with extended half life
|
PT2498801T
(pt)
|
2009-11-13 |
2018-05-02 |
Sanofi Aventis Deutschland |
Composição farmacêutica compreendendo despro36exendin-4(1-39)-lys6-nh2 e metionina
|
DE102010011919A1
(de)
|
2010-03-18 |
2011-09-22 |
Sanofi-Aventis Deutschland Gmbh |
Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin
|
US10029011B2
(en)
|
2009-11-13 |
2018-07-24 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
|
CA2797033C
(en)
|
2010-04-22 |
2021-10-19 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
AU2011247452B2
(en)
|
2010-04-27 |
2016-03-17 |
Zealand Pharma A/S |
Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
|
AR081975A1
(es)
|
2010-06-23 |
2012-10-31 |
Zealand Pharma As |
Analogos de glucagon
|
AP2013006671A0
(en)
|
2010-06-24 |
2013-01-31 |
Zealand Pharma As |
Glucagon analogues
|
SG187904A1
(en)
|
2010-08-30 |
2013-04-30 |
Sanofi Aventis Deutschland |
Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
JP6121330B2
(ja)
|
2010-09-28 |
2017-04-26 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
作用持続時間が増した改変ポリペプチド
|
US9161953B2
(en)
|
2010-12-22 |
2015-10-20 |
Amylin Pharmaceuticals, Llc |
GLP-1 receptor agonists for islet cell transplantation
|
WO2012136790A1
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Compositions comprising fusion proteins or conjugates with an improved half -life
|
WO2012136792A2
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Cck compositions
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
US20140221282A1
(en)
|
2011-05-25 |
2014-08-07 |
Astrazeneca Pharmaceuticals Lp |
Long duration dual hormone conjugates
|
JP6396211B2
(ja)
|
2011-07-04 |
2018-09-26 |
インペリアル・イノベイションズ・リミテッド |
新規化合物及び摂食行動に対するそれらの効果
|
EP2729481B1
(en)
|
2011-07-08 |
2018-10-17 |
Amylin Pharmaceuticals, LLC |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
KR101983982B1
(ko)
|
2011-08-29 |
2019-05-30 |
사노피-아벤티스 도이칠란트 게엠베하 |
2형 당뇨병 환자의 혈당 조절에 사용하기 위한 약제학적 병용물
|
AR087744A1
(es)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
|
EP2763690B1
(en)
|
2011-10-04 |
2015-11-25 |
Sanofi-Aventis Deutschland GmbH |
Lixisenatide for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
|
US20130096059A1
(en)
|
2011-10-04 |
2013-04-18 |
Jens Stechl |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
AU2012331053A1
(en)
|
2011-11-03 |
2014-05-29 |
Zealand Pharma A/S |
GLP-1 receptor agonist peptide gastrin conjugates
|
US10100097B2
(en)
|
2012-05-03 |
2018-10-16 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
IN2014DN09297A
(pt)
|
2012-05-16 |
2015-07-10 |
Glaxo Group Ltd |
|
US9745359B2
(en)
|
2012-05-18 |
2017-08-29 |
Adda Biotech Inc. |
Protein and protein conjugate for diabetes treatment, and applications thereof
|
DK2875043T3
(en)
|
2012-07-23 |
2017-03-27 |
Zealand Pharma As |
glucagon
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
UA116553C2
(uk)
|
2012-12-21 |
2018-04-10 |
Санофі |
Пептидна сполука - агоніст рецептора glp-1 i glp
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
US9789164B2
(en)
|
2013-03-15 |
2017-10-17 |
Longevity Biotech, Inc. |
Peptides comprising non-natural amino acids and methods of making and using the same
|
AU2014261111B2
(en)
|
2013-05-02 |
2017-03-16 |
Glaxosmithkline Intellectual Property Development Limited |
Therapeutic peptides
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
EA034322B1
(ru)
|
2013-10-17 |
2020-01-28 |
Зилэнд Фарма А/С |
Ацилированные аналоги глюкагона
|
TWI670281B
(zh)
|
2013-11-06 |
2019-09-01 |
西蘭製藥公司 |
Gip-glp-1雙重促效劑化合物及方法
|
WO2015067716A1
(en)
|
2013-11-06 |
2015-05-14 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
EP3077008B1
(en)
|
2013-12-06 |
2023-10-04 |
Jie Han |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
EP3080150B1
(en)
|
2013-12-13 |
2018-08-01 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
TW201609799A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重glp-1/gip受體促效劑
|
TW201609797A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重glp-1/升糖素受體促效劑
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽-4(exendin-4)胜肽類似物
|
US9895423B2
(en)
|
2014-01-09 |
2018-02-20 |
Sanofi |
Stabilized pharmaceutical formulations of insulin aspart
|
MX2016008979A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
|
EP3091965A1
(en)
|
2014-01-09 |
2016-11-16 |
Sanofi |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
MX2017005457A
(es)
|
2014-10-29 |
2017-07-04 |
Zealand Pharma As |
Metodos y compuestos agonistas de gip.
|
NZ733670A
(en)
|
2014-12-12 |
2021-12-24 |
Sanofi Aventis Deutschland |
Insulin glargine/lixisenatide fixed ratio formulation
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
KR20170137198A
(ko)
|
2015-04-16 |
2017-12-12 |
질랜드 파마 에이/에스 |
아실화된 글루카곤 유사체
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
AU2016338410B2
(en)
|
2015-10-14 |
2021-07-15 |
X-Therma, Inc. |
Compositions and methods for reducing ice crystal formation
|
US10294303B2
(en)
|
2015-12-23 |
2019-05-21 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
|
EP3551202B1
(en)
|
2016-12-06 |
2024-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
|
KR102502040B1
(ko)
|
2016-12-09 |
2023-02-24 |
질랜드 파마 에이/에스 |
아실화 glp-1/glp-2 이중 효능제
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
MX2019013919A
(es)
|
2017-06-20 |
2020-01-21 |
Amgen Inc |
Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
|
DK3774838T3
(da)
|
2018-04-10 |
2022-10-31 |
Sanofi Aventis Deutschland |
Lixisenatidsyntese med capping
|
JP7434169B2
(ja)
|
2018-04-10 |
2024-02-20 |
サノフィ-アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
固相からの固相結合ペプチドの切断方法
|
US20220152154A1
(en)
|
2019-03-08 |
2022-05-19 |
Amgen Inc. |
Growth differentiation factor 15 combination therapy
|